Series A financing led by Samsara Biocapital and Lightstone Ventures to advance PsiThera’s growing pipeline, starting with multiple ...

Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF) inhibitors were at significantly lower risk for hip and spine fractures compared with those receiving only ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Kids with polyarticular-course juvenile idiopathic arthritis ...

PsiThera, formerly Psivant Therapeutics, raised just over $47 million for oral drugs targeting “diseases long-constrained by ...

Nov. 16, 2005 (San Diego) — Patients with rheumatoid arthritis who do not respond to anti-tumor necrosis factor-alpha (anti-TNF-alpha) agents often respond to treatment with rituximab, according to a ...

A study from Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with Crohn’s disease. The resulting paper, “HLA DQA1*05 and risk of anti-TNF ...

Early treatment of pediatric Crohn’s disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn’s ...

Whether it’s safe to stop anti-TNF treatment in patients with inflammatory bowel disease (IBD) in remission remains unclear. In the Spanish EXIT study, anti-TNF withdrawal in selected patients with ...

WASHINGTON (Reuters) - U.S. health regulators have received more reports of rare blood cancer in young patients taking a class of anti-inflammatory drugs used to treat digestive disorders. The drugs, ...

NEW YORK (Reuters) - An experimental treatment for rheumatoid arthritis being developed by Johnson & Johnson and Schering-Plough Corp appeared to be effective and very safe in three late-stage trials, ...